Bellmunt Risk Score validated for survival prediction in Lu-PSMA-617 therapy

A retrospective external validation study evaluated the Bellmunt Risk Score (BRS), based on ECOG performance status, hemoglobin level, and liver metastases, in 243 mCRPC patients treated with [Lu]Lu-PSMA-617 at an independent center. The study reported that median overall survival decreased significantly with increasing BRS category (24.0 to 8.7 months across BRS 0 to 3, p<0.001), and that BRS 2 and BRS 3 remained independent predictors of shortened survival after adjusting for prior treatment lines. The authors concluded that the BRS is a pragmatic and robust prognostic tool, successfully validated in this independent cohort.

Most relevant for: Patients with metastatic castration-resistant prostate cancer being considered for or undergoing [Lu]Lu-PSMA-617 radioligand therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.